

Lecture 18 – Immunization & Vaccines

The production of a state of immunity in a subject - a way of preventing infectious disease **symptoms** by boosting the immune response.

1. **Passive immunization:** provides transient immune protection by transfer of antibodies or lymphocytes, or other means of assisting the immune response

No memory

- natural: placental transfer (IgG) and breastfeeding (IgA)
- artificial: antibody/serum therapy (snake bite/diphtheria). These antibodies are typically obtained from horses. *What are the advantages and disadvantages of this source of Ab?*

high production of Ab

foreign : generate human Ab against anti-venom horse Ab

2. **Active immunization:** provides long-lasting immunity (memory)

- natural (*get sick*)
- artificial – Vaccination (vacca = latin for cow).

B^{mem}
T_H^{mem} T_C^{mem}



Case Study - Small pox (Variola virus) Lethality rate 30% (European) - 90% (Native American).

1000 BC – documented cases.

1567 AD – Powdered small pox scabs used intra-nasally as vaccine.


1721 AD – Variolation introduced in England – scratching skin with sample from scabs (1/1000 mortality rate)

1800 AD – Jenner uses cowpox to vaccinate against smallpox

1940 AD - Vaccinia virus (similar to variola virus) used in current vaccines (1/10⁶ mortality)

1977 AD – Smallpox eradicated globally.

(global vaccination program)



2. Vaccination

Vaccine: a vehicle containing a **form of an antigen** that is administered to induce memory B and T cells specific for that antigen. Generally protect against disease, not infection.

B-cell vaccine: Introduction of a **B-cell epitope** to produce antibodies that interfere with pathogen life-cycle (neutralizing antibodies). Note this also requires the formation of T_H cells.

T-cell vaccine: Presentation of **antigens on MHC I** to stimulate formation of T_C memory cells.

Adjuvant: Increase immunogenicity of the antigen by causing inflammation.

- i. Aluminum salts (Alum)
 - ii. MF59: oil-water emulsion - Slow release of antigen
 - iii. AS04: Alum + lipopolysaccharides. → inflammation.
- long term exposure


Booster shots - Measles 9 months 15 months 5 yrs.

What do booster shots do?

increase # of memory cells (long period of immunity)

Properties of a Useful Vaccine?

- immunogenic.
- Safe
- Cheap.
- Stable
- one dose
- no needle



Some theoretical considerations for vaccine development:


- i) Acute versus chronic disease.

T because decent immune response chance of preventing symptoms → poor immune response i.e. vaccine ineffective

- ii) Time course of disease versus timing of secondary response:
shorter incubation period of the disease may not allow rapid memory response and, therefore, disease may not be inhibited.

Which pathogen A, or B should you make a vaccine against?


B - 2 day response is fast enough to prevent symptoms





How would you provide protective immunity against a pathogen with a short incubation period (e.g. Ebola)?

many booster shots \Rightarrow circulating Ab. \Rightarrow inactivate "fast" pathogen

Importance of High Levels of Vaccination - Herd Immunity.



Reported Measles Cases, United States, 1960-1996



Cervical Cancer – Herpes Papillomavirus (HPV) 99% of cases. Vaccine Cervarix – 99% effective.

Historical Rates of one dose (3 recommended)

2007 – 25%


2011 – 53%

2012 – 53%

dead
 dead
 bacteria
 vaccine
 safer
 (no poss.
 of getting
 disease)

live
 vaccine
 more effective
 - path. antigen
 - infection

present

Vaccine	Target	Strengths (+) and Weaknesses (-)
Denatured (inactive) toxins/sub-units	Toxin (e.g. diphtheria, tetanus)	<ul style="list-style-type: none"> (-) Not as effective (-) 100% inactivation, reproducible.
Killed organism	Bacteria (Typhoid) & Viruses (Salk polio)	<ul style="list-style-type: none"> (-) 100% inactivation required.
Surface carbohydrate + carrier protein (conjugate vaccine)	Bacteria (H. influenza)	<ul style="list-style-type: none"> (+) reproducible <ul style="list-style-type: none"> - stable carrier. protein - produce Ab response against carrier.
Capsid proteins purified or recombinant	Virus (HepB, HPV)	<ul style="list-style-type: none"> Tc response required. - weak antigen presentation (DC only) - limited production of antigen.
Attenuated virus <ul style="list-style-type: none"> i) natural non-infectious virus e.g. cowpox ii) passage on non-human host. iii) recombinant 	Virus (Sabin polio, mumps, measles)	 <p>The pathogenic virus is isolated from a patient and grown in human cultured cells. The cultured virus is used to infect monkey cells. The virus acquires many mutations that allow it to grow well in monkey cells. The virus no longer grows well in human cells (it is attenuated) and can be used as a vaccine.</p>
Viral vector encoded	Virus (HepB)	Virus i. insert antigen from pathogen (safe) Virus → vaccine.